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Celebrating 10 Years of The Journal of Molecular
Diagnostics
This issue of The Journal of Molecular Diagnostics marks our
10th year of publication, and indeed much has changed in
molecular pathology. Health care pundits predict double-
digit growth in molecular diagnostic testing for many years
to come, making it the fastest-growing sector of the clinical
laboratory. Indeed, the Journal’s sponsoring societies, the
Association for Molecular Pathology (AMP) and the Ameri-
can Society for Investigative Pathology (ASIP), have seen
monumental growth in membership, and their areas of fo-
cus have been catapulted forward by new technology and
scientific knowledge, paralleled closely by the JMD.
The JMD serves as a hub for the molecular diagnostic
arena, addressing scientific and technological advances,
along with practical issues critical for new assay devel-
opment and validation as well as the delivery of quality
molecular testing from the clinical laboratory. The JMD
has expanded from four issues to six, with a marked in-
crease in published manuscripts, reviews, and other fea-
tures. Its influence and timeliness are reflected in the dra-
matic increase in impact factor, from 2.901 in 2006 to 3.478
in 2007.1 JMD will undoubtedly continue this trajectory,
based on the expansion of new diagnostic applications,
including the promise of personalized medicine, with
treatments that target specific molecular alterations in
tumors and drug dosing tuned to an individual’s enzy-
matic capabilities.
This contrasts with 10 years ago, when our horizons
were more limited. Nucleic acid preparation was manual,
and real-time amplification with automated fluorescent
detection had not yet entered our clinical laboratories.
We were only beginning to envision pairing molecular diag-
nostic tools with novel targeted therapeutics. Arrays were in
their infancy, with expression analysis still being performed
by differential display or series analysis of gene expression
(SAGE). Quantitative measurements were still performed
using competitive polymerase chain reaction (PCR). The
changes in these 10 years have been extraordinary.
Coincident with the JMD’s 10-year mark, many thanks
are due. Several visionary members of AMP and ASIP
worked tirelessly to bring the journal from idea to reality (see
the following Guest Editorial for more information on JMD’s
inception). Several managing editors have also been
critical to the JMD’s evolution, beginning with Priscilla
Markwood, who labored to help launch the new journal;
Maria Giorla, who shaped it as it grew; and Dr. Audra
Cox, whose expertise now guides the JMD. Mark So-
bel, Executive Officer of AMP/ASIP, has been a stalwart
supporter and friend. The Associate Editors and editorial
board members have devoted hours to the critical review
and guidance of manuscripts through the peer review
process, while authors have trusted us with their work.
I have thoroughly and sincerely enjoyed my years as
Editor-in-Chief of the JMD and have likely learned more
from this role than any of the Journal’s readers. After 10
years, however, it is time to turn the leadership over to
a new editor, and the announcement of the upcoming
search for a new Editor-in-Chief can be found in the
later pages of this issue.
It is impossible to predict the future of our field, but it is
also irresistible (see the Associate Editors’ predictions in
an additional Guest Editorial). No doubt much of the
molecular testing done 10 years from now will be per-
formed by automated analyzers, which will likely be min-
iaturized and often at the bedside. We will use information
gathered from the genome, transcriptome, proteome,
and metabolome. Treatments will be chosen based on
molecular signatures that fine-tune a patient’s diagnosis.
These will include assessment of host factors important in
disease progression or resolution, in addition to markers
of the tumor or microbe itself that are indicative of sensi-
tivity and resistance to therapy. Disease susceptibility will
be measurable, and hopefully we will be attuned to pre-
ventative approaches that decrease a patient’s risk for
disease development. Many visionaries believe we will
carry our genome sequences in our pockets, perhaps
digitally encoded on our medical insurance or pharmacy
cards. It is my hope that the JMD will thrive in this era, and
I look forward with great enthusiasm to the many changes
that lie ahead.1
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